NRAS and cancer: Although sotorasib was considered KRAS G12C specific and is FDA-approved for KRAS G12C mediated cancers only (Skoulidis et al., 2021), studies have indicated it may be suitable for other NRAS or HRAS G12C-mutated cancer, delivering potential to revolutionise the way in which the drug can be used.